BAN (Comedian) 24-hour volatility at 185.8%: Whale on-chain activity and Solanameme momentum drive pump followed by a sharp drop
Bitget Pulse2026/03/18 22:03Volatility Overview
In the past 24 hours, BAN price surged from a low of $0.0598 to a high of $0.1710, resulting in an amplitude of 185.8%. The current quote is $0.0616, marking a sharp pullback of about 64% from the peak. Trading volume soared to approximately $57.19 million, which is significantly higher than usual, reflecting high activity.
Brief Analysis of Price Movements
- Dominance of on-chain whale activity: Monitoring indicates whales swept liquidity, driving prices rapidly up to around $0.1689, followed by signs of selling; there is no confirmed external event.
- Solana meme coin momentum: Benefiting from the meme boom within the Solana ecosystem, trading volume climbed and the price briefly rose more than 20%.
Market Perspectives and Outlook
Prevailing community sentiment has turned cautious. Binance Square discussions are focused on on-chain liquidity and whale moves, suggesting the pump is driven by short-term momentum with warnings of further correction risks. Analysts highlight the high volatility of meme coins, noting that future trends depend on the Solana ecosystem and capital rotation, with no clear rebound forecast.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
